C4 therapeutics reports full year 2021 financial results and recent business highlights

– data from cohort a of the ongoing phase 1/2 trial of cft7455, a novel ikzf1/3 degrader, accepted for presentation at the american association for cancer research (aacr) annual meeting –

CCCC Ratings Summary

Quant